-+ 0.00%
-+ 0.00%
-+ 0.00%

Ionis Pharmaceuticals (IONS) Stock Looks Fully Priced On Its 67% Slide

Simply Wall St·11/21/2026 16:09:05
Listen to the news

Ionis Pharmaceuticals has seen its share price slide sharply in 2026, which puts fresh attention on whether the current valuation is still in line with what its sales can support. With sentiment now heavily influenced by product launches, revised expectations and headline risk, the central issue is how much revenue the business needs to justify where the stock trades today.

  • The share price is down 66.6% year to date, so the question for you is whether the current level now fairly reflects the value investors are placing on Ionis Pharmaceuticals and its sales base.
  • Recent developments around drugs such as Tryngolza, DAWNZERA and the Alzheimer’s candidate diranersen can shape how investors think about future revenue growth, profit potential and the timing of cash flows tied to Ionis Pharmaceuticals sales.
  • The analysts covering Ionis Pharmaceuticals have run their own numbers. See what analysts think Ionis Pharmaceuticals's shares could be worth.

The stock's next move may depend on whether the current market price looks aligned with what Ionis Pharmaceuticals is generating, and may be able to generate, from its sales.

If this sharp reset in Ionis Pharmaceuticals has you questioning what sales-based pricing looks like elsewhere, it can help to compare against a wider group of 40 high quality undervalued stocks.

Does Ionis Pharmaceuticals Look Pricey on Sales?

P/S fits Ionis Pharmaceuticals because investors are currently focused on what its commercial and pipeline drugs might support in terms of revenue rather than earnings.

The stock trades on a P/S of 4.6x, which is below the broader Biotechs sector at 10.1x and under the peer group average of 10.2x. Based on the tailored fair multiple that reflects Ionis Pharmaceuticals specific growth profile, margins, size and risk mix, the current P/S still screens as overvalued. Because the sharp cut to TRYNGOLZA guidance has reset expectations around near term sales, the gap between the market price and that fair multiple suggests investors are paying up for the rest of the portfolio and for successful execution on newer launches. Explore the numbers behind Ionis Pharmaceuticals's P/S valuation.

NasdaqGS:IONS P/S Ratio as at Nov 2026
NasdaqGS:IONS P/S Ratio as at Nov 2026

The Ionis Pharmaceuticals Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the Ionis Pharmaceuticals valuation puzzle leaves off. They spell out what kind of growth, margins and earnings path would need to hold for the stock to look meaningfully cheaper or more expensive than today’s price. Each one treats fair value as a thesis about how Ionis Pharmaceuticals' business might play out over time, which you can track as new information emerges on the Community page.

One of the top narratives on Ionis Pharmaceuticals: 35% undervalued

This Narrative is the bearish analyst Narrative on Simply Wall St, built on the most pessimistic analyst price target and forecasts, not one person's view.

"Concerns around launch execution are central, with several research notes pointing to a slower than expected TRYNGOLZA ramp and reimbursement friction…"

Discover why this Narrative puts Ionis Pharmaceuticals at 35% undervalued.

One more piece to weigh before deciding what Ionis Pharmaceuticals is worth

Before you put too much weight on today’s share price or P/S multiple, it helps to see where the analyst community thinks this business could be a few years from now. Explore where analysts expect Ionis Pharmaceuticals to be in a few years.